Latest Breaking News On - Zhifei lvzhu biopharma - Page 1 : comparemela.com

OrbiMed Asia V plans to raise $1.1 billion, OrbiMed Flagship IX seeks $1.9 billion and OrbiMed Royalty & Credit Opportunities $1.75 billion.

United statesZhifei lvzhu biopharmaKintor pharmaNewsoara biopharmaNikang pharmaCoherus bioTaicang san diegoJunshi biosciencesHansoh pharmaOrbimed asiaShanghai jemincare pharmaceuticalsOrion corporationOrbimed flagshipOrbimed royaltyGreater chinaJemincare pharmaceuticals